Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

Karuna Therapeutics, Inc. Common Stock (KRTX)

Pharmaceutical Preparations

https://www.karunatx.com

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

99 HIGH STREET, 26TH FLOOR
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/28/2019

Market Cap

12,599,275,119

Shares Outstanding

37,890,000

Weighted SO

37,893,579

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ISEE --.--%

BPMC --.--%

AMLX --.--%

DAWN --.--%

XFOR --.--%

INZY --.--%

ABOS --.--%

MREO --.--%

TERN --.--%

Beta

1.1490

Last Div

0.0000

Range

158.375-329.99

Chg

0.0900

Avg Vol

971825

Mkt Cap

12599275119

Exch

NASDAQ

Country

US

Phone

857 449 2244

DCF Diff

325.2666

DCF

4.5634

Div Yield

0.0000

P/S

19264.9467

EV Multiple

-25.1454

P/FV

9.9354

Div Yield %

0.0000

P/E

-29.5160

PEG

0.8628

Payout

0.0000

Current Ratio

19.3062

Quick Ratio

18.6075

Cash Ratio

2.7275

DSO

2734.7095

DIO

7044.8648

Op Cycle

9779.5743

DPO

1455.4938

CCC

8324.0804

Gross Margin

-1.6009

Op Margin

-756.5398

Pretax Margin

-662.0948

Net Margin

-645.5474

Eff Tax Rate

0.1046

ROA

-0.3160

ROE

-0.3079

ROCE

-0.3902

NI/EBT

0.9750

EBT/EBIT

0.8752

EBIT/Rev

-756.5398

Debt Ratio

0.0125

D/E

0.0133

LT Debt/Cap

0.0109

Total Debt/Cap

0.0131

Int Coverage

0.0000

CF/Debt

-23.1195

Equity Multi

1.0654

Rec Turnover

0.1335

Pay Turnover

0.2508

Inv Turnover

0.0518

FA Turnover

0.0319

Asset Turnover

0.0005

OCF/Share

-10.2120

FCF/Share

-10.2892

Cash/Share

33.4246

OCF/Sales

-589.9373

FCF/OCF

1.0076

CF Coverage

-23.1195

ST Coverage

-135.7084

CapEx Coverage

-132.2657

Div&CapEx Cov

-132.2657

P/BV

9.9354

P/B

9.9354

P/S

19264.9467

P/E

-29.5160

P/FCF

-32.4109

P/OCF

-32.2983

P/CF

-32.2983

PEG

0.8628

P/S

19264.9467

EV Multiple

-25.1454

P/FV

9.9354

DPS

0.0000

Latest Headlines (EST)

Seeking Alpha Dec 31, 02:49 Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Seeking Alpha Dec 31, 02:49 Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Seeking Alpha Dec 31, 02:49 Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Seeking Alpha Dec 31, 02:49 Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Benzinga Dec 28, 08:35 Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Zacks Investment Research Dec 26, 17:44 Yes Virginia, There Is a Santa Claus Rally Benzinga Dec 26, 14:02 Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst Benzinga Dec 26, 14:02 Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst Zacks Investment Research Dec 26, 11:20 Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers Benzinga Dec 26, 08:03 Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say

Revenue Product Segmentation